The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, Baystreet.ca News Commentary, The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion ...

Phase III data show the Braftovi regimen significantly improves overall survival and response versus chemo as a frontline treatment for advanced tumors.

The contractual framework governing the CVRs is clearly defined. Holders are entitled to 100% of the net proceeds from a contingent payment valued at $30.5 million, provided the drug candidate ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.